Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Heart Diseases
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 95 Years
Enrollment: 5,302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Hypertension
Interventions: methyldopa vs. clonidine, clonidine patch; Drug
Lead sponsor: Afshan B. Hameed, M.D.; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Metabolic Syndrome
Interventions: High Linoleic Safflower Oil; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 50 Years to 69 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hypertension, Left Ventricular Hypertrophy
Interventions: Ultrafiltration; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Menopause, Hypertension
Interventions: Taekwondo training; Behavioral
Lead sponsor: Kosin University; Other
Eligibility: 65 Years to 85 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pulmonary Hypertension
Interventions: SonoVue, Placebo; Drug
Lead sponsor: Bracco Diagnostics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: LL-BMT1; Drug
Lead sponsor: MediPrint Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hypertension
Interventions: Computer, Reduction in financial barrier, Computer intervention & reduction of financial barrier, Control; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Harrisburg, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device; Combination Product
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 35 more

Conditions: Hypertension
Interventions: Azilsartan medoxomil and olmesartan, Olmesartan, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 80
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 77 more

Conditions: Glaucoma, Open-angle, Ocular Hypertension
Interventions: Combination IOP Lowering Therapy; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Ocular Hypertension, Ocular Surface Disease
Interventions: Latanoprost, Travatan Z; Drug
Lead sponsor: Santen SAS; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Cirrhosis, Liver, Portal Hypertension, Ascites Hepatic
Interventions: Withings Home Blood Pressure Device and Scale, Standard of Care; Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: Rodatristat Ethyl 300 mg BID, Rodatristat Ethyl 600 mg BID, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 3 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Orange, Connecticut

Conditions: Hypertension and Coronary Artery Disease
Interventions: Celecoxib, placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 50 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: Gainesville, Florida • Houston, Texas

Conditions: Hypertension
Interventions: Sodium Watcher Program-Hypertension, Usual Care; Behavioral
Lead sponsor: Misook L. Chung; Other
Eligibility: 18 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Lifestyle-related Condition, Obesity, Sedentary Lifestyle, PreDiabetes, Hypertension
Interventions: Health Coaching; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Macular Degeneration, Glaucoma, Diabetic Retinopathy, Choroidal Disease
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more

Conditions: Glaucoma
Interventions: App; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma
Interventions: rtACS Stimulation, Sham Intervention; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 50 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Cataract
Interventions: Pred Forte, EconoPred Plus, Prednisolone Acetate; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Identifying Genes That May Increase the Risk for Heart Disease in African Americans

A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy

Healthy Oils for Women (HOW Study)

Hypertension in Hemodialysis

Taekwondo Training and Postmenopausal Women With Stage-2 Hypertension

Safety of SonoVue on Pulmonary Hemodynamics

Social Worker in an Eye-Care Service

Study of LL-BMT1 in Patients With Elevated Intraocular Pressure

Collaboration to Reduce Disparities in Hypertension

Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients

Multiple-Ascending Dose in Japanese Patients Bridging Study

Intergenerational Blood Pressure Study

Effect of Celecoxib on Markers of Vascular Inflammation

Sodium Watchers Program - Hypertension

MyLife: A Digital Health Coaching Program

Tracking Optical Coherence Tomography

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

An App-based Instructional Platform to Improve Eye Drop Recall

A Study Using Transorbital Alternating Current Stimulation for People With Glaucoma

A Comparison of Three Different Formulations of Prednisolone Acetate 1%